Premium
Decreased interleukin‐21 expression in skin and blood in advanced mycosis fungoides
Author(s) -
Kabasawa Miyoko,
Sugaya Makoto,
Oka Tomonori,
Takahashi Naomi,
Kawaguchi Makiko,
Suga Hiraku,
Miyagaki Tomomitsu,
Takahashi Takehiro,
Shibata Sayaka,
Fujita Hideki,
Asano Yoshihide,
Tada Yayoi,
Kadono Takafumi,
Okochi Hitoshi,
Sato Shinichi
Publication year - 2016
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/1346-8138.13278
Subject(s) - mycosis fungoides , dermatology , medicine , immunology , lymphoma
Interleukin ( IL )‐21 is regarded as a potent antitumor agent, which increases the cytotoxicity of both natural killer ( NK ) and CD 8 + T cells. In this study, we investigated the role of IL ‐21 in mycosis fungoides ( MF ). IL ‐21 mRNA expression levels in patch and plaque MF were significantly higher than those in normal skin. IL ‐21 mRNA expression levels in tumor MF were significantly decreased compared with those in patch and plaque MF . Interestingly, mRNA expression levels of IL ‐21 in MF lesional skin significantly correlated with those of T‐helper type‐1 cytokines/chemokines such as CXCL 10, CXCL 11 and γ‐interferon. Immunohistochemistry showed that IL ‐21 was expressed by keratinocytes in patch and plaque MF . Furthermore, serum IL ‐21 levels in patients with tumor MF were significantly lower than those of healthy controls and plaque MF . Thus, IL ‐21 expression was significantly downregulated in skin and blood of patients with tumor MF , which may contribute to progression of MF . Our study suggests that recombinant IL ‐21 would be a promising therapy for MF.